Stacy Barajas
Family · Munster, INNPI 1457892937
Payments from drug & device makers
Across 58 payments — averaging $72.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$744
- Insulet Corporation$648
- Novo Nordisk$579
- Amgen$326
- Tandem Diabetes Care, Inc.$264
- BETA Bionics, Inc.$260
- plus $1K from 12 others
What the payments were for
- Food & beverage$3,93793%
- Education$2907%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 9 | $744 |
| Insulet Corporation | 8 | $648 |
| Novo Nordisk | 13 | $579 |
| Amgen(2 entities) | 3 | $326 |
| Tandem Diabetes Care, Inc. | 2 | $264 |
| BETA Bionics, Inc. | 3 | $260 |
| Medtronic | 2 | $248 |
| Incyte Corporation | 2 | $232 |
| Dexcom, Inc. | 3 | $188 |
| Daiichi Sankyo Inc. | 2 | $156 |
| Ascendis Pharma Endocrinology Inc | 1 | $125 |
| Cequr Corporation | 1 | $117 |
| Xeris Pharmaceuticals, Inc. | 1 | $95 |
| Sanofi | 1 | $95 |
| AstraZeneca | 3 | $79 |
| Recordati_rare_diseases_inc. | 2 | $34 |
| Ascensia Diabetes Care US Inc. | 1 | $22 |
| EUSA Pharma (US) LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FREESTYLE LIBRE 3$518
- Omnipod$482
- iLet Bionic Pancreas$408
- t:slim X2 Insulin Pump with Control-IQ$264
- JAKAFI$232
- INPEN SMART INSULIN DELIVERY SYSTEM$144
- iLet Insulin Infusion Kit Inset$136
- iLet Insulin Infusion Kit Contact Detach$136
- Yorvipath$125
- TEPEZZA$124
- EVENITY$119
- CeQur Simplicity$117
- Ozempic$114
- MINIMED 780G$104
- DEXCOM G7 GSS (161)$102
How this compares
$4,227 in reported general payments places this provider in the 90th percentile of 4,392 family providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 312 | $566,112 |
| TrulicityDulaglutide | 147 | $267,760 |
| JardianceEmpagliflozin | 101 | $139,421 |
| Tresiba Flextouch U-200Insulin Degludec | 65 | $104,545 |
| MounjaroTirzepatide | 56 | $101,819 |
| JanuviaSitagliptin Phosphate | 57 | $71,387 |
| FarxigaDapagliflozin Propanediol | 62 | $65,488 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 27 | $55,205 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 40 | $49,486 |
| Tresiba Flextouch U-100Insulin Degludec | 55 | $49,409 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 42 | $48,435 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 52 | $41,848 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 43 | $37,577 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 203 | $36,922 |
| Novolog FlexpenInsulin Aspart | 98 | $32,526 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $579 | $577,711337 claims |
| AstraZenecaFarxiga | $79 | $65,48862 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,392 family providers in Indiana.
Other family in Munster
- Monika VasicMunster$25K
- Sharon HennMunster$19K
- Donna WinterrowdMunster$17K
- Jacquelyn AdleyMunster$16K
- Tina SizemoreIndianapolis$888K
- Kathalene Keller RineyEvansville$383K
- Robin AndersonPortage$333K
- Marla MosesIndianapolis$142K
- Justin BrownFort Wayne$142K
- Lacey MatheisEvansville$139K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.